ArticleCancer research2014
Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.
Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Macrophage-intrinsic and IL-9-dependent arginine metabolism promotes lung tumor growth.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Functional diversity and regulation of IL-9-producing T cells in cancer immunotherapy.Cancer letters · 2024Review
- Th9 and Th17 Cells in Human Ulcerative Colitis-Associated Dysplastic Lesions.Clinical Medicine Insights. Oncology · 2024Article
- Dual Functions of T Lymphocytes in Breast Carcinoma: From Immune Protection to Orchestrating Tumor Progression and Metastasis.Cancers · 2023Review
- T cells in health and disease.Signal transduction and targeted therapy · 2023Review
- The Dichotomy of Interleukin-9 Function in the Tumor Microenvironment.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023Review
- Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.Exploration of targeted anti-tumor therapy · 2023Review
- Mouse pulmonary interstitial macrophages mediate the pro-tumorigenic effects of IL-9.Nature communications · 2022Article
- The Roles of IRF-8 in Regulating IL-9-Mediated Immunologic Mechanisms in the Development of DLBCL: A State-of-the-Art Literature Review.Frontiers in oncology · 2022Review
- The Role ofCells · 2021Article
- IL-9-producing T cells: potential players in allergy and cancer.Nature reviews. Immunology · 2021Review
- Interleukin-9 in Immunopathology ofFrontiers in cellular and infection microbiology · 2021Article
- Targeting the IL-9 pathway in cancer immunotherapy.Human vaccines & immunotherapeutics · 2020Review
- The Role of Interleukin-9 in Cancer.Pathology oncology research : POR · 2020Review
- Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer.The Journal of clinical investigation · 2020Article
- IL-9 and IL-9-producing cells in tumor immunity.Cell communication and signaling : CCS · 2020Review
- A combination of inhibitors of glycolysis, glutaminolysis andOncology letters · 2019Article
- The dichotomous function of interleukin-9 in cancer diseases.Journal of molecular medicine (Berlin, Germany) · 2019Review
- T Helper 9 Cells: A New Player in Immune-Related Diseases.DNA and cell biology · 2019Review
- Effect of Th9/IL-9 on the growth of gastric cancer in nude mice.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The tolerogenic cytokine IL9 promotes T regulatory cell function and allergic airway inflammation, but it has not been extensively studied in cancer. In this report, we used IL9-deficient mice to investigate the effects of IL9 in multiple models of breast and colon cancer development. Eliminating endogenous IL9 enabled sensitization of host T cells to tumors, leading to their early rejection without the requirement of vaccines or immunomodulatory therapies. Notably, IL9-deficient mice acquired immunologic memory, which actively protected from residual disease and tumor rechallenge, an effect linked to activation of CD8(+) T cells. Depletion of either CD8(+) or CD4(+) T cells abolished the benefits of IL9 loss to tumor control. Adoptive transfer experiments showed that T cells from tumor-rejecting IL9-deficient mice retained their effector competency in wild-type animals. Moreover, neutralizing IL9 antibody phenocopied the effects of IL9 gene deletion by slowing tumor progression in wild-type animals. Our results show the ability of IL9 to function as an inhibitor of adaptive immunity that prevents the formation of immunologic memory to a growing tumor, highlighting the potential for IL9 neutralization as a unique tool for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.